28502074|t|Causes and consequences of mesenteric embolization after endovascular aorto-iliac intervention - a nested case control study
28502074|a|Causes and consequences of mesenteric embolization after endovascular aorto-iliac procedures have not been studied adequately. Consecutive patients with mesenteric embolization after endovascular aorto-iliac intervention between 2011 and 2015 (case - group, n = 9) were investigated and compared with age, gender and procedure - matched random controls (n = 36). Compared to the control group, a higher proportion of patients with mesenteric embolization were current smokers (89% vs. 53%; P = 0.048) and had renal insufficiency at admission (44% vs. 11%; P = 0.019). In patients treated for aorto-iliac occlusive disease, aortic irregularity (shagginess) was more severe (P = 0.015), visceral thrombus volume was larger (P = 0.004) and operation - time was longer (P = 0.009) among the case - group. However, no difference s were found between cases with mesenteric embolization caused by endovascular aortic aneurysm repair versus controls. Myoglobin, arterial blood lactate, aspartate aminotransferase, alanine aminotransferase and pancreatic amylase levels were elevated in 100%, 67%, 89%, 89%, 89% and 56% of patients with mesenteric embolization, respectively. Overall in-hospital mortality among cases was 33% (3/9). The in-hospital mortality was 17% (1/6) in patients treated with open abdomen therapy, of whom five were managed with stomas. Smoking cessation, careful patient selection and procedure planning with identification of severe shaggy aortas might prevent mesenteric embolization during aorto-iliac procedures. In suspected cases of mesenteric embolization, elevated myoglobin and arterial blood lactate may be indicative of this complication. Aspartate and alanine aminotranferases, as well as pancreatic amylase, are also relevant tests to assess the extent of organ ischaemia. Damage control with open abdomen therapy and the creation of stomas seem justifiable in order to improve survival in this complex situation.
28502074	0	6	Causes	T078	C0085978
28502074	11	23	consequences	T169	C0686907
28502074	27	50	mesenteric embolization	T047	C0267407
28502074	57	69	endovascular	T029	C0524425
28502074	70	81	aorto-iliac	T023	C1268307
28502074	82	94	intervention	T061	C0184661
28502074	99	124	nested case control study	T062	C0027775
28502074	125	131	Causes	T078	C0085978
28502074	136	148	consequences	T169	C0686907
28502074	152	175	mesenteric embolization	T047	C0267407
28502074	182	194	endovascular	T029	C0524425
28502074	195	206	aorto-iliac	T023	C1268307
28502074	207	217	procedures	T061	C0184661
28502074	232	239	studied	T062	C2603343
28502074	252	263	Consecutive	T080	C1707491
28502074	264	272	patients	T101	C0030705
28502074	278	301	mesenteric embolization	T047	C0267407
28502074	308	320	endovascular	T029	C0524425
28502074	321	332	aorto-iliac	T023	C1268307
28502074	333	345	intervention	T061	C0184661
28502074	369	373	case	T169	C0868928
28502074	376	381	group	T078	C0441833
28502074	395	407	investigated	T169	C1292732
28502074	426	429	age	T032	C0001779
28502074	431	437	gender	T032	C0079399
28502074	442	451	procedure	T169	C2700391
28502074	454	461	matched	T080	C1708943
28502074	462	468	random	T080	C0439605
28502074	469	477	controls	T080	C0243148
28502074	504	517	control group	T096	C0009932
28502074	521	527	higher	T080	C0205250
28502074	528	538	proportion	T081	C1709707
28502074	542	550	patients	T101	C0030705
28502074	556	579	mesenteric embolization	T047	C0267407
28502074	593	600	smokers	T033	C0337664
28502074	634	653	renal insufficiency	T047	C1565489
28502074	657	666	admission	T058	C0809949
28502074	696	704	patients	T101	C0030705
28502074	717	728	aorto-iliac	T023	C1268307
28502074	729	746	occlusive disease	T047	C0003838
28502074	748	754	aortic	T023	C0003483
28502074	755	767	irregularity	T080	C0205271
28502074	790	796	severe	T080	C0205082
28502074	810	818	visceral	T082	C0442045
28502074	819	827	thrombus	T046	C0087086
28502074	828	834	volume	T081	C0449468
28502074	862	871	operation	T061	C0543467
28502074	874	878	time	T079	C0040223
28502074	912	916	case	T169	C0868928
28502074	919	924	group	T078	C0441833
28502074	935	948	no difference	T033	C3842396
28502074	970	975	cases	T169	C0868928
28502074	981	1004	mesenteric embolization	T047	C0267407
28502074	1005	1011	caused	T078	C0085978
28502074	1015	1050	endovascular aortic aneurysm repair	T061	C0918249
28502074	1058	1066	controls	T080	C0243148
28502074	1068	1077	Myoglobin	T116,T123	C0027078
28502074	1079	1101	arterial blood lactate	T109,T121	C1991210
28502074	1103	1129	aspartate aminotransferase	T116,T126	C0004002
28502074	1131	1155	alanine aminotransferase	T116,T126	C0001899
28502074	1160	1178	pancreatic amylase	T116,T126	C0301812
28502074	1179	1185	levels	T080	C0441889
28502074	1239	1247	patients	T101	C0030705
28502074	1253	1276	mesenteric embolization	T047	C0267407
28502074	1300	1321	in-hospital mortality	T080	C0085556
28502074	1328	1333	cases	T169	C0868928
28502074	1353	1374	in-hospital mortality	T080	C0085556
28502074	1392	1400	patients	T101	C0030705
28502074	1414	1418	open	T082	C0175566
28502074	1419	1426	abdomen	T029	C0000726
28502074	1427	1434	therapy	T169	C0039798
28502074	1454	1461	managed	T057	C1273870
28502074	1467	1473	stomas	T017	C1955856
28502074	1475	1492	Smoking cessation	T055	C0085134
28502074	1502	1519	patient selection	T062	C0242802
28502074	1524	1533	procedure	T169	C2700391
28502074	1534	1542	planning	T169	C1301732
28502074	1548	1562	identification	T080	C0205396
28502074	1566	1572	severe	T080	C0205082
28502074	1580	1586	aortas	T023	C0003483
28502074	1601	1624	mesenteric embolization	T047	C0267407
28502074	1632	1643	aorto-iliac	T023	C1268307
28502074	1644	1654	procedures	T061	C0184661
28502074	1669	1674	cases	T169	C0868928
28502074	1678	1701	mesenteric embolization	T047	C0267407
28502074	1712	1721	myoglobin	T116,T123	C0027078
28502074	1726	1748	arterial blood lactate	T109,T121	C1991210
28502074	1756	1766	indicative	T078	C3146298
28502074	1775	1787	complication	T046	C0009566
28502074	1789	1798	Aspartate	T116,T126	C0004002
28502074	1803	1827	alanine aminotranferases	T116,T126	C0001899
28502074	1840	1858	pancreatic amylase	T116,T126	C0301812
28502074	1878	1883	tests	T169	C0039593
28502074	1887	1893	assess	T052	C1516048
28502074	1898	1904	extent	T082	C0439792
28502074	1908	1913	organ	T023	C0178784
28502074	1914	1923	ischaemia	T046	C0022116
28502074	1925	1931	Damage	T169	C1883709
28502074	1932	1939	control	T080	C0243148
28502074	1945	1949	open	T082	C0175566
28502074	1950	1957	abdomen	T029	C0000726
28502074	1958	1965	therapy	T169	C0039798
28502074	1974	1982	creation	T061	C0441513
28502074	1986	1992	stomas	T017	C1955856
28502074	2022	2029	improve	T033	C0184511
28502074	2030	2038	survival	T052	C0038952
28502074	2047	2054	complex	T080	C0439855